
Kronos Bio KRON
Quarterly report 2025-Q1
added 05-08-2025
Kronos Bio Interest Expense 2011-2026 | KRON
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Kronos Bio
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 3.89 M | 3 K | 76 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.89 M | 3 K | 1.32 M |
Quarterly Interest Expense Kronos Bio
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.89 M | - | 1 K | - | 1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.89 M | 1 K | 1.3 M |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Aquestive Therapeutics
AQST
|
6.55 M | $ 4.14 | 0.36 % | $ 443 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
10.1 M | $ 8.39 | 4.5 % | $ 230 M | ||
|
Ardelyx
ARDX
|
4.5 M | $ 6.06 | 1.94 % | $ 1.46 B | ||
|
Arcutis Biotherapeutics
ARQT
|
443 K | $ 23.93 | 1.27 % | $ 3.04 B | ||
|
Arvinas
ARVN
|
-400 K | $ 11.36 | 4.7 % | $ 805 M | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
5.26 M | $ 61.99 | 1.57 % | $ 8.29 B | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Assembly Biosciences
ASMB
|
117 K | $ 29.09 | 0.28 % | $ 326 M | ||
|
Actinium Pharmaceuticals
ATNM
|
1.09 M | $ 1.13 | 15.26 % | $ 35.3 M | ||
|
Atossa Therapeutics
ATOS
|
-6 K | $ 5.19 | -3.36 % | $ 44.7 M | ||
|
Atara Biotherapeutics
ATRA
|
3.79 M | $ 5.0 | 0.2 % | $ 62.7 M | ||
|
Autolus Therapeutics plc
AUTL
|
36.7 M | $ 1.41 | -0.35 % | $ 375 M | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Axon Enterprise
AXON
|
286 M | $ 411.97 | -0.2 % | $ 31.2 B | ||
|
Aytu BioScience
AYTU
|
-512 K | $ 2.65 | -1.12 % | $ 16.6 M | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
BioCardia
BCDA
|
3 K | $ 1.18 | -1.67 % | $ 7.87 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
59.3 M | $ 9.59 | 6.26 % | $ 1.98 B | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
4.68 M | $ 3.05 | 1.51 % | $ 260 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-7.26 M | $ 9.46 | -3.47 % | $ 612 M | ||
|
BioVie
BIVI
|
4.3 M | $ 1.46 | 2.81 % | $ 2.16 M | ||
|
BioLineRx Ltd.
BLRX
|
9.07 M | $ 2.32 | 4.98 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
15.3 M | $ 56.04 | 0.96 % | $ 10.7 B | ||
|
BioNTech SE
BNTX
|
14.2 M | $ 91.64 | 0.5 % | $ 27.2 B | ||
|
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | ||
|
BioXcel Therapeutics
BTAI
|
-3.52 M | $ 1.18 | -0.42 % | $ 14.4 M |